SARS-CoV-2 enables IL-6 and induces CNS immune responses. Type I IFN is also dysregulated and can affect innate and acquired immunity. In this case series, we present two cases who present with ATM as a complication of COVID-19 infection. First case is a 45yo individual who presented with progressive bilateral lower extremities paresthesia and weakness. Hyperreflexia and motor weakness 4/5 in lower extremities. PMH was significant for recent COVID-19 pneumonia requiring intubation. Additionally, a case of 74yo individual who presented with acute onset of walking difficulty. PMH was significant for recent COVID-19 infection. Hyperreflexia and motor weakness 4/5 in lower extremities with positive Babinski sign. Workup in both cases revealed spinal cord involvement with T2-hyperintense lesions. All workup for other etiologies for ATM like MS, NMO, autoimmune or paraneoplastic syndrome was unremarkable and COVID-19 infection though to be the underlying etiology at this time. Both patients were offered treatment with IV steroids. Decision was made to follow up with serial imaging to start the patient on immunosuppressive therapy if ATM shows any progression.
Those two cases highlights that ATM can present as a sequela to COVID-19 infection or vaccination via the impact SARS-CoV-2 has on the immune system.